ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2369
    Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
  • Abstract Number: 2691
    Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Abstract Number: 250
    Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
  • Abstract Number: 2266
    Treatment Preferences in Patients with Axial Spondyloarthritis
  • Abstract Number: 2791
    Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review
  • Abstract Number: 1389
    Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
  • Abstract Number: 252
    Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
  • Abstract Number: 124
    Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
  • Abstract Number: 2343
    Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
  • Abstract Number: 1237
    Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
  • Abstract Number: 510
    Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
  • Abstract Number: 522
    Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
  • Abstract Number: 1404
    Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
  • Abstract Number: 821
    Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)
  • Abstract Number: 1097
    Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
  • « Previous Page
  • 1
  • …
  • 186
  • 187
  • 188
  • 189
  • 190
  • …
  • 198
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology